Benign Prostatic Hyperplasia – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Benign Prostatic Hyperplasia – Pipeline Review, H2 2020’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia

– The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects

– The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aiviva BioPharma Inc

Aphios Corp

Aquestive Therapeutics Inc

ASKA Pharmaceutical Co Ltd

BCWorld Pharm Co Ltd

Boryung Pharmaceutical Co Ltd

Chengdu Dikang Pharmaceuticals Co Ltd

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

DongKoo Bio & Pharma Co Ltd

Dongkook Pharmaceutical Co Ltd

Everon Biosciences Inc

GemVax & KAEL Co Ltd

Hanmi Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Huons Co Ltd

Jeil Pharmaceutical Co Ltd

Kolmar Pharma Co Ltd

Kwang Dong Pharmaceutical Co Ltd

Mezzion Pharma Co Ltd

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

Sophiris Bio Inc

ValiRx Plc

Veru Inc

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

Introduction

Benign Prostatic Hyperplasia- Overview

Benign Prostatic Hyperplasia- Therapeutics Development

Benign Prostatic Hyperplasia- Therapeutics Assessment

Benign Prostatic Hyperplasia- Companies Involved in Therapeutics Development

Benign Prostatic Hyperplasia- Drug Profiles

Benign Prostatic Hyperplasia- Dormant Projects

Benign Prostatic Hyperplasia- Discontinued Products

Benign Prostatic Hyperplasia- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Aiviva BioPharma Inc, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Aphios Corp, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Aquestive Therapeutics Inc, H2 2020

Benign Prostatic Hyperplasia – Pipeline by ASKA Pharmaceutical Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by BCWorld Pharm Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Curadis GmbH, H2 2020

Benign Prostatic Hyperplasia – Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Everon Biosciences Inc, H2 2020

Benign Prostatic Hyperplasia – Pipeline by GemVax & KAEL Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Health Ever Bio-Tech Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Huons Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Kolmar Pharma Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Kwang Dong Pharmaceutical Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Mezzion Pharma Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Nymox Pharmaceutical Corp, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Ono Pharmaceutical Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Sophiris Bio Inc, H2 2020

Benign Prostatic Hyperplasia – Pipeline by ValiRx Plc, H2 2020

Benign Prostatic Hyperplasia – Pipeline by Veru Inc, H2 2020

Benign Prostatic Hyperplasia – Pipeline by XuanZhu Pharma Co Ltd, H2 2020

Benign Prostatic Hyperplasia – Dormant Projects, H2 2020

Benign Prostatic Hyperplasia – Dormant Projects, H2 2020 (Contd..1), H2 2020

Benign Prostatic Hyperplasia – Dormant Projects, H2 2020 (Contd..2), H2 2020

Benign Prostatic Hyperplasia – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports